On January 6, 2023 bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") reported that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million (Press release, bluebird bio, JAN 6, 2023, View Source [SID1234625960]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
bluebird bio was granted two PRVs upon the US Food and Drug Administration (FDA) approvals of ZYNTEGLO (betibeglogene autotemcel) for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and SKYSONA (elivaldogene autotemcel) for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively. On December 29, 2022, bluebird closed the sale of its first PRV for $102 million.
"The sale of our second priority review voucher further bolsters our financial position and provides an important source of non-dilutive funding for the company," said Chris Krawtschuk, chief financial officer, bluebird bio. "Strengthening the company’s balance sheet – as we have continued to do through demonstrated fiscal discipline and the sale of both PRVs – ensures we enter 2023 with significant momentum behind the commercial launches of our two FDA-approved gene therapies, and the opportunity ahead in sickle cell disease."
bluebird received a payment of $95 million upon closing of the transaction, which occurred simultaneously with the parties entering into the agreement. Jefferies LLC acted as the exclusive financial advisor to bluebird for this transaction.
About the Rare Pediatric Disease Priority Review Voucher Program
The Rare Pediatric Disease Priority Review Voucher Program is intended to encourage development of new drug and biological products for the prevention and treatment of certain rare pediatric diseases. Under this program, upon approval, the US Food and Drug Administration awards priority review vouchers to sponsors of rare pediatric disease product applications that meet certain criteria. The voucher can be redeemed to receive priority review of a subsequent marketing application for a different product. PRVs may be sold or transferred, and there is no limit on the number of times a PRV can be transferred.